27
Views
0
CrossRef citations to date
0
Altmetric
Drug Profile

Clinical experience with lanreotide for the treatment of acromegaly

&
Pages 139-149 | Published online: 10 Jan 2014

References

  • Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary2(1), 29–41 (1999).
  • Melmed S. Acromegaly pathogenesis and treatment. J. Clin. Invest.119(11), 3189–3202 (2009).
  • Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin. Endocrinol. (Oxf).69(3), 432–435 (2008).
  • Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab.93(1), 61–67 (2008).
  • Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur. J. Endocrinol.159(2), 89–95 (2008).
  • Giustina A, Chanson P, Bronstein MD et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab.95(7), 3141–3148 (2010).
  • Weber MM. Akromegalie. In: Erkrankungen von Hypothalamus und Hypophyse. Jockenhövel F, Gerhards G (Eds). Petersenn Unimed, Bremen, Germany, 111–121 (2011).
  • Melmed S, Casanueva F, Cavagnini F et al. Consensus statement: medical management of acromegaly. Eur. J. Endocrinol.153(6), 737–740 (2005).
  • Gonzalez B, Vargas G, Espinosa-de-los-Monteros AL, Sosa E, Mercado M. Efficacy and safety of radiotherapy in acromegaly. Arch. Med. Res.42(1), 48–52 (2011).
  • Attanasio R, Epaminonda P, Motti E et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J. Clin. Endocrinol. Metab.88(7), 3105–3112 (2003).
  • Abs R, Verhelst J, Maiter D et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab.83(2), 374–378 (1998).
  • Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab.96(5), 1327–1335 (2011).
  • Freda PU. Somatostatin analogs in acromegaly. J. Clin. Endocrinol. Metab.87(7), 3013–3018 (2002).
  • Colao A, Auriemma RS, Rebora A et al. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin. Endocrinol. (Oxf.)71(2), 237–245 (2009).
  • Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary13(1), 60–67 (2010).
  • Petersenn S, Schopohl J, Barkan A et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, Phase II trial. J. Clin. Endocrinol. Metab.95(6), 2781–2789 (2010).
  • Neggers SJ, de Herder WW, Feelders RA, van der Lely AJ. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. Pituitary14(3), 253–258 (2011).
  • Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur. J. Endocrinol.160(4), 529–533 (2009).
  • Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab.92(12), 4598–4601 (2007).
  • Neggers SJ, van der Lely AJ. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm. IGF Res.21(3), 129–133 (2011).
  • van der Lely AJ, Bernabeu I, Cap J et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur. J. Endocrinol.164(3), 325–333 (2011).
  • Trainer PJ, Drake WM, Katznelson L et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med.342(16), 1171–1177 (2000).
  • van der Lely AJ, Hutson RK, Trainer PJ et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet358(9295), 1754–1759 (2001).
  • Schreiber I, Buchfelder M, Droste M et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur. J. Endocrinol.156(1), 75–82 (2007).
  • Buhk JH, Jung S, Psychogios MN et al. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J. Clin. Endocrinol. Metab.95(2), 552–558 (2010).
  • Jaquet P, Gunz G, Saveanu A et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur. J. Endocrinol.153(1), 135–141 (2005).
  • Saveanu A, Lavaque E, Gunz G et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J. Clin. Endocrinol. Metab.87(12), 5545–5552 (2002).
  • Ciccarelli A, Daly A, Beckers A. Lanreotide Autogel® for acromegaly: a new addition to the treatment armamentarium. Treat. Endocrinol.3(2), 77–81 (2004).
  • Bevan JS, Newell-Price J, Wass JA et al. Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin. Endocrinol. (Oxf.)68(3), 343–349 (2008).
  • Salvatori R, Nachtigall LB, Cook DM et al. Effectiveness of self or partner administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary13(2), 115–122 (2010).
  • Adelman DT, Burgess A, Davies PR. Nurse evaluation of long-acting somatostatin analogue injection devices: a quantitative study. Presented at: 8th Annual ENETS Conference. Lisbon, Portugal, 9–11 March 2011.
  • Hu M, Tomlinson B. Pharmacokinetic evaluation of lanreotide. Expert Opin Drug Metab. Toxicol.6(10), 1301–1312 (2010).
  • Valery C, Paternostre M, Robert B et al. Biomimetic organization: octapeptide self-assembly into nanotubes of viral capsid-like dimension. Proc. Natl Acad. Sci USA100(18), 10258–10262 (2003).
  • de Herder WW, Lamberts SW. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr. Opin. Oncol.14(1), 53–57 (2002).
  • Paniagua AE, Bernabeu I, Leskela S, Marazuela M. Lanreotide autogel-induced tumour shrinkage in thyrotropin-secreting pituitary macroadenomas. Clin. Endocrinol. (Oxf.)74(3), 406–408 (2011).
  • Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J. Exp. Clin. Cancer Res.29, 19 (2010).
  • Croxtall JD, Scott LJ. Lanreotide Autogel: a review of its use in the management of acromegaly. Drugs68(5), 711–723 (2008).
  • Steffin B, Gutt B, Bidlingmaier M, Dieterle C, Oltmann F, Schopohl J. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur. J. Endocrinol.155(1), 73–78 (2006).
  • Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp. Clin. Endocrinol. Diabetes113(3), 139–144 (2005).
  • Molitch ME. Lanreotide Autogel in the management of acromegaly. Drugs68(5), 724 (2008).
  • Kuhn JM, Legrand A, Ruiz JM, Obach R, De Ronzan J, Thomas F. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br. J. Clin. Pharmacol.38(3), 213–219 (1994).
  • Heron I, Thomas F, Dero M et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J. Clin. Endocrinol. Metab.76(3), 721–727 (1993).
  • Somatuline® Depot (lanreotide) injection, prescribing information. Ipsen Pharma, Paris, France (2011).
  • Antonijoan RM, Barbanoj MJ, Cordero JA et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J. Pharm. Pharmacol.56(4), 471–476 (2004).
  • Cendros JM, Peraire C, Troconiz IF, Obach R. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism54(10), 1276–1281 (2005).
  • Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J. Clin. Endocrinol. Metab.93(8), 2957–2968 (2008).
  • Bronstein M, Musolino N, Jallad R et al. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin. Endocrinol. (Oxf)63(5), 514–519 (2005).
  • Troconiz IF, Cendros JM, Peraire C et al. Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months. Clin. Pharmacokinet.48(1), 51–62 (2009).
  • Garrido MJ, Cendros JM, Ramis J, Peraire C, Obach R, Troconiz IF. Pharmacodynamic modeling of the effects of lanreotide autogel on growth hormone and insulin-like growth factor 1. J. Clin. Pharmacol. doi:10.1177/0091270011399761 (2011) (Epub ahead of print).
  • Castinetti F, Saveanu A, Morange I, Brue T. Lanreotide for the treatment of acromegaly. Adv. Ther.26(6), 600–612 (2009).
  • Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary13(1), 18–28 (2010).
  • Toledano Y, Rot L, Greenman Y et al. Efficacy of long-term lanreotide treatment in patients with acromegaly. Pituitary12(4), 285–293 (2009).
  • Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin. Endocrinol. (Oxf.)64(2), 209–214 (2006).
  • Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J. Clin. Endocrinol. Metab.94(10), 3746–3756 (2009).
  • Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin. Endocrinol. (Oxf.)68(3), 473–480 (2008).
  • Kelly P, Maher KT, Chew SL, Monson JP, Grossman AB, Jenkins PJ. A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide. Endocr. Pract.16(2), 191–197 (2010).
  • Ronchi CL, Boschetti M, Degli Uberti EC et al. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin. Endocrinol. (Oxf.)67(4), 512–519 (2007).
  • Schopohl J, Strasburger CJ, Caird D et al. Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp. Clin. Endocrinol. Diabetes119(3), 156–162 (2011).
  • Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin. Endocrinol. (Oxf.)69(2), 299–305 (2008).
  • Lombardi G, Minuto F, Tamburrano G et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J. Endocrinol. Invest.32(3), 202–209 (2009).
  • Maiza JC, Vezzosi D, Matta M et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin. Endocrinol. (Oxf.)67(2), 282–289 (2007).
  • Lucas T, Astorga R, Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin. Endocrinol. (Oxf.)58(4), 471–481 (2003).
  • Mao ZG, Zhu YH, Tang HL et al. Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur. J. Endocrinol.162(4), 661–666 (2010).
  • Attanasio R, Lanzi R, Losa M et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr. Pract.14(7), 846–855 (2008).
  • Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J. Clin. Endocrinol. Metab.90(3), 1856–1863 (2005).
  • Melmed S, Sternberg R, Cook D et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J. Clin. Endocrinol. Metab.90(7), 4405–4410 (2005).
  • Zatelli MC, Piccin D, Ambrosio MR, Bondanelli M, degli Uberti EC. Antiproliferative effects of somatostatin analogs in pituitary adenomas. Pituitary9(1), 27–34 (2006).
  • Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol. (Oxf.)61(2), 209–215 (2004).
  • Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur. J. Endocrinol.152(4), 569–574 (2005).
  • Marzullo P, Ferone D, Di Somma C et al. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary1(2), 115–120 (1999).
  • Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a Phase III trial. Clin. Endocrinol. (Oxf)65(3), 320–326 (2006).
  • Abrams P, Alexopoulou O, Abs R, Maiter D, Verhelst J. Optimalization and cost management of lanreotide-Autogel therapy in acromegaly. Eur. J. Endocrinol.157(5), 571–577 (2007).
  • Alexopoulou O, Abrams P, Verhelst J et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur. J. Endocrinol.151(3), 317–324 (2004).
  • Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J. Clin. Endocrinol. Metab.94(5), 1500–1508 (2009).
  • Maggio EE, Grasso P. Oral delivery of octreotide acetate, a synthetic analog of somatostatin, in Intravail®, improves uptake, serum half-life, and bioavailability over subcutaneous injection: a pharmacokinetic study in male Swiss Webster mice. Regul. Pept.167(2–3), 233–238 (2011).
  • Chieffo C, Ryan M, Malott C, Frohman LA. Pharmacodynamics and safety of an 84-mg subcutaneous octreotide hydrogel implant for the treatment of acromegaly. Presented at: The Annual Meeting of the Endocrine Society. Boston, MA, USA, 4–7 June 2011 (Abstract).
  • Chieffo C, Ryan M, Malott C, Gadelha MR, Frohman LA. Rates of biochemical response in patients with acromegaly treated with a subcutaneous octreotide hydrogel implant. Presented at: The Annual Meeting of the Endocrine Society. Boston, MA, USA, 4–7 June 2011 (Abstract).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.